ZymoGenetics ZGEN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymoGenetics ZGEN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (193)	9/11/2009 11:11:10 AM
From: Steve Lokness	of 210

Interesting reaction to ZGEN news yesterday (reminds me of reaction to ALTH news a few days ago); UPDATE 1-ZymoGenetics' arthritis drug hits roadblock Thu Sep 10, * Says drug fails to meet disease-control activity level * Says further exploratory analyses underway Sept 10 (Reuters) - ZymoGenetics Inc (ZGEN.O) said preliminary results from a mid-stage trial of its experimental rheumatoid arthritis drug did not support a direct move to late-stage trials. The company said the drug atacicept failed to meet the pre-specified level of disease-control activity. ZymoGenetics's licensee Merck Serono, a unit of German drugmaker Merck KGaA (MRCG.DE), was developing atacicept as a treatment for systemic lupus erythematosus, multiple sclerosis and rheumatoid arthritis. ZymoGenetics said further exploratory analyses was on and Merck Serono has not made any decision regarding rheumatoid arthritis as a potential indication for atacicept. The company said trials for lupus and multiple sclerosis indications are currently ongoing. Shares of ZymoGenetics closed down 5 cents at $6.47 Thursday on Nasdaq. (Reporting by Anand Basu

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next